A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Dave Singh,B R Leaker,Malcolm Boyce, M.A. Nandeuil,Sara Collarini,Fabrizia Mariotti,Debora Santoro,Peter J. Barnes

Pulmonary Pharmacology & Therapeutics（2016）

引用 39|浏览20

暂无评分

摘要

CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases. The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model.

查看译文

关键词

Allergen challenge,PDE4 inhibitor,CHF6001

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要